By comparison, 509 of 706 primary breast adenocarcinoma tumor samples obtain from participants in the BCIRG 001 clinical trial [16] were found to be NMT2 negative (Table 1 and Fig. 2c). Here, NMT2 is linked to breast adenocarcinoma.